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Background: Controversies surrounding the efficacy of surgical sealants against alveolar air leaks (AAL) in lung
surgery abound in the literature. We sought to test the sealing efficacy of a novel synthetic sealant, TissuePatch™ in
an in vitro lung model.
Methods: The lower lobe of freshly excised swine lung (n = 10) was intubated and ventilated. A superficial
parenchymal defect (40 × 25 mm) was created, followed by AAL assessment. After sealant application, AAL was
assessed again until burst failure occurred. The length of defect was recorded to evaluate the elasticity of the
sealant.
Results: Superficial parenchymal defects resulted in AAL increasing disproportionally with ascending maximal
inspiratory pressure (Pmax). Multiple linear regression analysis revealed strong correlation between AAL and Pmax,
compliance, resistance. After sealant application, AAL was sealed in all ten tests at an inspired tidal volume (TVi) of
400 ml, in nine tests at TVi = 500 ml, in seven at TVi = 600 ml and in five at TVi = 700 ml. The mean burst pressure
was 42 ± 9 mBar. Adhesive and cohesive sealant failures were found in six and three tests respectively. The length
of defect before sealant failure was 8.9 ± 4.9% larger than that at TVi = 400 ml, demonstrating an adequate elasticity
of this sealant film.
Conclusions: TissuePatch™ may be a reliable sealant for alternative or adjunctive treatment for repair of superficial
parenchymal defects in lung surgery. The clinical benefits of this sealant should be confirmed by prospective,
randomised controlled clinical trials.Abstrakt
Hintergrund: Die Wirksamkeit von chirurgischen Klebstoffen zur Prävention von alveolo-pleuralem Luftleck (APL) ist
trotz zunehmenden klinischen Anwendungen in Lungenchirurgie immer noch kontrovers diskutiert. Wir evaluierten
die Abdichtungswirksamkeit von einem neuartigen synthetischen Kleber, TissuePatch™ mittels eines in vitro
Lungenmodels.
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Methode: Der Unterlappen von frisch entnommenen Schweinlungen (n = 10) wurde intubiert und beatmet. Eine
pleurale Läsion (40 × 25 mm) wurde erstellt und APL mit steigendem inspiratorischem Tidalvolumen (TVi)
untersucht. Nach Applikation von TissuePatch™ wurde APL auf die gleiche Weise gemessen bis zur Auftritt von
Kleberbruch. Zur Untersuchung der Elastizität des Klebers wurde die Länge der pleuralen Läsion gemessen.
Ergebnis: Pleurale Läsion führte bei aufsteigendem maximalem inspiratorischem Druck (Pmax) zu
überproportionalem Anstieg von APL. Multiple lineare Regressionsanalyse ergab eine starke Korrelation zwischen
APL und Pmax, Lungencompliance sowie Widerstand. Nach der Applikation von Klebstoff wurde APL bei
TVi = 400 ml in allen zehn Testen versiegelt, bei TVi = 500 ml in neun Testen, bei TVi = 600 ml in sieben und bei
TVi = 700 ml in fünf Testen. Der mittlere Pmax, der zu Kleberbruch führte, betrug 42 ± 9 mBar. Bei den Versuchen
wurden adhäsiver und kohäsiver Kleberbruch in jeweils sechs und drei Testen gefunden. Die Länge der pleuralen
Läsion vor dem Kleberbruch war 8,9 ± 4,9% größer als die bei TVi = 400 ml.
Schlussfolgerung: Unsere Versuche zeigten eine zuverlässige Versiegelung von TissuePatch™ unter mechanischer
Ventilation. Die klinische Nützlichkeit vom Kleber als unterstützende Maßnahme zur Prävention von alveolo-
pleuralem Luftleck in Lungenchirurgie sollte durch prospektive, randomisierte kontrollierte klinische Studien
bestätigt werden.
Keywords: Lung, Pleural air leak, Sealant, In vitro modelFigure 1 TissuePatchTM synthetic sealant film.Background
Alveolar air leaks (AAL) resulting from superficial lung
parenchymal defects are a common intra- and post-
operative complication in lung surgery, especially in
pleural decortication, dissection of firm pleural adhesion
and division of incomplete fissures [1]. They result in
delayed chest tube removal, prolonged hospital stay and
marked patient discomfort as well as higher health care
costs [1,2]. In the last decade, various surgical sealants
have been developed and become progressively wide-
spread to prevent AAL in lung surgery [1,3]. As adjuncts
to conventional closure techniques, application of surgi-
cal sealants has been reported to be able to reduce mean
duration of AAL, duration to chest tube removal [4-6]
and the length of hospital stay [4,6,7], as well as inci-
dence of postoperative empyema [8,9]. However, accord-
ing to the current Cochrane review and meta-analysis of
Malapert et al., randomized controlled clinical trials
assessing surgical sealants in treating AAL demonstrated
inconsistent results, raising a question regarding their
efficacy [1,10].
TissuePatch™ (TP, Tissuemed Ltd, Leeds, UK) is a
novel synthetic sealant, which is self-adhesive and ab-
sorbable (Figure 1). It consists of TissueBond (a bioadhe-
sive polymer) and polylactide-co-glycolide (PLGA). The
active chemistry of TissueBond forms cross-links at pro-
teins that are present at the site of application, while
PLGA functions as a barrier and structural layer and is
largely absorbed within 70 days. Since the introduction
in 2007, the original product, TissuePatch3™ has been
used as an adjunctive treatment in control and preven-
tion of air, blood or fluid leakage in various surgical pro-
cedures. Recently, TP as the new generation product is
available. In the present study, we sought to examine thesealing efficacy of TP in treating AAL by means of an
in vitro lung model.
Methods
Experimental protocol
Lungs were freshly excised from German Landrace pigs
(around 80 kg) without preference in gender, which were
euthanized in a local slaughterhouse. Within two hours
after harvest, the lungs were dissected along the trachea
until the tracheal bifurcation was reached. The lower
lobe was selectively intubated due to the greater facility
compared to upper lobe. It was then inflated and
immersed in warm water to ensure its impermeability.
After being connected to the ventilation machine (Evita,
Dräger, Lübeck, Germany), the lobe was ventilated in a
volume-controlled mode with positive end-expiratory
pressure (PEEP) of 5 mBar, I:E ratio of 1:2 and
Figure 2 A superficial lung defect was created in a previously
marked area of 40 × 25 mm on the inflated lower lobe.
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inflated when inspired tidal volume (TVi) ≥ 400 ml,
while over-inflation was observed when TVi ≥ 800 ml. A
superficial parenchymal lesion (40 × 25 mm) was created
on the inflated lobe (Figure 2). Surgical knots were then
tied on the cranial and caudal edge of the lesion and
served as markers for the measurement of lesion length.
Inspiratory volume was increased in steps, recording the
respiratory parameters including the expiratory tidal vol-
ume (TVe), Pmax, mean inspiratory pressure (Pmean),
plateau inspiratory pressure (Pplat), resistance and com-
pliance for each subsequent step until a Pmax of 40
mBar was reached. AAL was calculated as the difference
between TVi and TVe. Sealing was considered, if AAL
was ≤ 20 ml.
Thereafter, the sealant was applied according to the
usage guide, respecting a safety margin of 1 cm to all
sides. Mild pressure was applied for a period of 60 sec-
ond to the sealant film to ensure full adhesion. The lobe
was then ventilated again with TVi rising slowly from
100 mL. Commencing at 400 ml TVi, the same respira-
tory parameters were measured again. In the moment
that sealant failure occurred, Pmax was recorded as the
burst pressure. The burst failure was categorized intoTable 1 Air leak assessment before sealant application
TVi (ml) Air leak (ml) Pmax (mBar) Pplat (mBar) P
400 105 ± 51 24 ± 4 14 ± 1
500 153 ± 64 29 ± 4 16 ± 2
600 214 ± 75 34 ± 5 17 ± 2
700 270 ± 87 38 ± 4 19 ± 2
800 330 ± 92 39 ± 1 21 ± 2
900 380 ± 110 41 ± 3 25 ± 3
1000 438 ± 119 39 ± 1 32 ± 3
Pmax =maximal inspiratory pressure.
Pmean =mean inspiratory pressure.
Pplat = plateau inspiratory pressure.
TVi = inspired tidal volume.adhesive or cohesive failure. Adhesive failure was consid-
ered, if the sealant failure occurred at the interface be-
tween the sealant and the parenchymal defect. Cohesive
failure was defined as the failure within the sealant.
Finally, the lung specimens containing the parenchy-
mal lesion along with the attached sealant were resected
and fixed with 10% formalin. The specimens were fur-
ther embedded in paraffin, and processed to obtain sec-
tions for haematoxylin-eosin staining.
Statistical analysis
The normality of variables was tested by the
Kolmogorov-Smirnov one-sample test. Descriptive statis-
tics are presented as mean ± standard deviation in case
of normal distribution. Categorical variables are
expressed as percentages. Continuous data was com-
pared using student t-test. Multiple linear regression
analysis was used to determine the ventilation para-
meters correlated with AAL. Statistical significance was
assumed if p < 0.05. All statistical evaluation was per-
formed using SPSS (version 16.0 for Windows; SPSS,
Inc., Chicago, IL).
Results
After establishing the experimental procedures, four
pilot tests were performed. The results from pilot tests
were not included in the data set or statistical analysis.
Subsequently, a total of ten consecutive tests were
undertaken. One TP film was applied on one lower lobe
in every single test. The recorded ventilation parameters
and measured AAL after creation of a superficial paren-
chymal lesion are listed in Table 1. With ascending in-
spiratory pressure, AAL increased disproportionally.
Multiple linear regression analysis revealed strong cor-
relation between AAL and Pmax, compliance and resist-
ance (p < 0.001, p = 0.01 and p = 0.002, respectively).
After application of the sealant film, AAL was sealed
in all ten tests at TVi of 400 ml, in nine tests at TVi of
500 ml, in seven tests at TVi of 600 ml and in five tests
at TVi of 700 ml (Figure 3). As TVi increased ≥ 700 ml,mean (mBar) Compliance (ml/mBar) Resistance (mBar/l/s)
8 ± 1 34 ± 7 4 ± 1
9 ± 1 33 ± 6 5 ± 1
10 ± 1 32 ± 5 5 ± 1
11 ± 1 32 ± 5 5 ± 1
11 ± 1 30 ± 5 6 ± 1
12 ± 0 27 ± 4 7 ± 1
13 ± 0 20 ± 5 9 ± 1
Figure 3 AAL was significantly reduced after application of sealant film at moderate ventilation.
Figure 4 Photomicrograph of histological sections showed the
sealant layer (arrow) attaching densely the underlying
parenchymal lesion.
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800 ml and Pmax of 42 mBar (AAL = 0 ml) and in an-
other at TVi of 900 ml and Pmax of 50 mBar (AAL =
20 ml). One test demonstrated complete sealing of AAL
even at TVi >1000 ml and Pmax > 60 mBar. The mean
burst pressure was 42 ± 9 mBar. Adhesive and cohesive
sealant failures were found in six and three tests respect-
ively. The inter-suture distance before burst failure was
8.9 ± 4.9% larger than that at TVi of 400 ml, indicating
an adequate elasticity of this sealant film.
Haematoxylin-eosin staining of the lung specimen
sealed by TP showed the layer of adhesive polymer
attaching densely the underlying parenchymal lesion
(Figure 4). The PLGA film was detached during proces-
sing of the samples and was not visible.
Discussion
As adjuncts to suturing or stapling, various surgical sea-
lants have been developed and progressively practised in
treating AAL in the last decade. According to a survey
of European Association for Cardio-Thoracic Surgery
and European Society of Thoracic Surgeons, more than
60% of surgeons used sealants in the practice routinely
or when indicated [3]. However, the sealant use was
mostly not based on clinical evidence. This is believed tobe due to inconsistent data of the published clinical
trials assessing the sealing efficacy of surgical sealants. In
the current Cochrane review including a total of 16 ran-
domized controlled clinical trials investigating the sea-
lants for preventing air leaks after pulmonary resections,
only three trials demonstrated a significant reduction in
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Post-operative chest tube time was significantly reduced
in treatment group only in three trails. Significant differ-
ence in duration of air leaks was only found in six out
of twelve clinical trails. Aside from some design flaws of
these studies, length of hospital stay and duration of
chest tube are inadequate primary endpoints to examine
the sealant’s efficacy, as they are determined not only by
AAL, but also by various other factors including relevant
co-morbidities, inadequate post-operative pain control,
prolonged fluid output. In contrast, the in vitro lung
model in the present study provides a reliable means to
assess AAL quantitatively and is able to test the burst
pressure of sealant. Furthermore, the elasticity of sealant
has also been evaluated. More clinical relevance could
be found to compare the sealing efficacy of different sea-
lants in treating AAL with this in vitro model.
TP is a novel, fully synthetic, self-adhesive sealant
patch, which is biodegradable. It consists of TissueBond
as an adhesive polymer, PLGA and methylene blue.
Since the first launch in 2007, the original product, Tis-
suePatch3TM has been progressively widespread as an
adjunct to seal leakage of air, chylous fluid and blood in
lung surgery, thyroidectomy, major neck surgery as well
as in the prevention of cerebrospinal fluid leaks follow-
ing neurosurgery. In the present study, we demonstrated
the strong sealing efficacy of TP as the new generation
product under mechanical ventilation. The mean burst
pressure exceeded the upper limit of the inspiratory
pressure, which is typical in most clinical settings
(Pmax ≤ 40 mBar). In the present experiment, certain
variation in the size of ventilated lower lobes could not
be totally avoided. However, we did not observe remark-
able difference in this regard during the tests. It could be
explained that the lungs were harvested from the pigs in
almost the same weight (around 80 kg). In all tests, the
lower lobe was fully inflated when TVi was 400 ml or
higher, indicating the absence of significant difference in
the size of lower lobes.
In a recent in vitro experiment comparing the sealing
efficacy of six different sealants including TissuePatch-
DuralTM (TPD, Tissuemed Ltd, Leeds, UK) similar to
TissuePatchTM, Pedersen et al. fixed harvested porcine
lungs in a Plexiglas chamber filled with isotonic saline
[11]. After sealant application on deflated lungs, the
lungs were ventilated with incremental peak airway pres-
sure and air leaks were assessed by visual inspection of
air bubbles in submersion tests. Their results demon-
strated a very low median burst pressure of TPD (25
mBar). The sealant never withstood peak pressures
higher than 30 mBar. Compared to the in vitro model of
the present experiment, certain factors may have biased
their study to the disadvantage of TPD. Firstly, the TPD
film was applied to deflated lungs, whereas themanufacturer recommends that the lung should be ¾
inflated during application. The subsequent lung re-
inflation and stretching may have deteriorated the bond-
ing between the adhesive polymer and lung surface due
to break of the cross-links. Furthermore, the time from
lung harvest to experimentation averaged as long as
24 hours. The resulted protein degradation may also
have impaired the cross-linking of polymer at lung tis-
sue, resulting in weaker sealing efficacy. Additionally, air
leakage assessment was performed via inspection of air
bubbles, and observer blinding was not possible due to
the obvious differences in product appearance in their
experiment.
Our results are comparable to the previously published
data of fibrin sealant patches in in vivo animal experi-
ments. In experimental studies with beagles, the working
group of Dr. Kawamura and Dr. Gika made defects on
the lung surface (5 × 10 mm and 5 × 20 mm, respect-
ively) and evaluated the sealing effect of fibrin glue
against air leakage with different methods of application.
In the group using collagen fleece, coated with fibrino-
gen and thrombin (TachoCombW, ZLB Behring Co.,
King of Prussia, PA, USA), the mean seal breaking pres-
sure was as high as 36 ± 6 mBar and slightly over 40
mBar, respectively [12,13].
TP is a ready to use sealant, which does not require
any preparation before application. It bonds to surgical
site in 60 seconds. Compared to TP, fibrin patches such
as TachoCombW or TachoSilW (Takeda, Zurich, Switzer-
land) need to be moistened before application, with
pressure required for 3 to 5 minutes after application
according to the usage guide. Furthermore, fibrin sea-
lants are typically derived from human or bovine blood
plasma, exposing patients to the potential risk of trans-
mission of blood-borne diseases [5,12]. Kamamura et al.
reported infection of human parvovirus B19 in more
than 20% of patients following use of fibrin sealant dur-
ing lung resection [14]. In this respect, application of TP
as a fully synthetic, biodegradable material completely
eliminates this risk. As a further advantage, TP can be
delivered thoracoscopically by means of a dedicated de-
livery system. Nevertheless, it is of utmost importance in
confirming the clinical benefits of TP by means of pro-
spective, randomised controlled clinical trials.
Conclusions
Based on our results, the use of TissuePatch™ in lung
surgery as a treatment for the adjunctive repair of super-
ficial parenchymal defects, even under aggressive mech-
anical ventilation, is recommended. In vitro evaluation
also demonstrated adequate elasticity of this sealant film.
The clinical and financial benefits of this sealant film
should be confirmed by prospective, randomised con-
trolled clinical trials.
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